OncoVista seeks IDE for breast cancer device

05/6/2008 | American City Business Journals

OncoVista Innovative Therapies has requested a meeting with the FDA to discuss an investigational device exemption for its AdnaTest Breast Cancer device. The company expects to reach an agreement with the agency on the design and review criteria for a study that will be used for its product approval application, CEO Alexander L. Weis said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC